A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC

被引：2
|
作者：
Cortiula, F. [1 ,2 ]
Naidoo, J. [3 ,4 ,5 ]
机构：
[1] Univ Hosp Udine, Dept Oncol, Udine, Italy
[2] Maastricht Univ, Sch Oncol & Reprod GROW, Maastricht, Netherlands
[3] Beaumont Hosp, Dublin, Ireland
[4] RCSI Univ Hlth Sci, Dublin, Ireland
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA
来源：
LUNG CANCER | 2023年 / 181卷
关键词：
CELL LUNG-CANCER; OPEN-LABEL; MULTICENTER; BENEFIT;
D O I：
10.1016/j.lungcan.2023.107256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC
    Piotrowska, Zofia
    Liu, Stephen V.
    Muzikansky, Alona
    Marcoux, Nicolas
    Banwait, Mandeep
    Stevens, Sara
    Goodwin, Kelly
    Lafferty, Tracey E.
    Ackil, Jennifer
    Krueger, Elizabeth A.
    Heist, Rebecca Suk
    Lin, Jessica Jiyeong
    Gainor, Justin F.
    Hata, Aaron N.
    Shaw, Alice Tsang
    Sequist, Lecia V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Osimertinib Called "Home Run" for EGFR-Mutant NSCLC
    Rose, Suzanne
    [J]. CANCER DISCOVERY, 2020, 10 (07) : 896 - 897
  • [3] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
    White, Maya N.
    Piotrowska, Zofia
    Stirling, Kevin
    Liu, Stephen V.
    Banwait, Mandeep K.
    Cunanan, Kristen
    Sequist, Lecia V.
    Wakelee, Heather A.
    Hausrath, Daniel
    Neal, Joel W.
    [J]. CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
  • [4] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
  • [5] Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
    Kian, W.
    Roisman, L. C.
    Dudnik, J.
    Chernomordikov, L.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Rosenberg, S. K.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S941 - S941
  • [6] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    [J]. ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [7] Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC
    Lu, Kevin
    Woodward, Brian D.
    Boys, Joshua
    Onaitis, Mark
    Husain, Hatim
    [J]. CLINICAL LUNG CANCER, 2024, 25 (01) : e58 - e61
  • [8] Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat
    Zugazagoitia, Jon
    Ferrer, Irene
    Paz-Ares, Luis
    [J]. LANCET ONCOLOGY, 2016, 17 (12): : 1622 - 1623
  • [9] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [10] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Remon, J.
    Steuer, C. E.
    Ramalingam, S. S.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
12345